Last updated: September 14, 2026
Lazertinib mesylate is an irreversible third-generation EGFR tyrosine kinase inhibitor marketed in the United States as Lazcluze. Johnson & Johnson commercializes it with Rybrevant, or amivantamab, for first-line treatment of locally advanced or metastatic non-small-cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations. The drug’s commercial value depends less on standalone tablet sales than on the success of the Lazcluze-Rybrevant combination against osimertinib-based therapy.
The product has a strong clinical entry position but faces three constraints: dependence on intravenous amivantamab, competition from AstraZeneca’s Tagrisso, and the absence of separately disclosed Lazcluze revenue. Its highest-value market opportunity is first-line EGFR-mutated metastatic NSCLC in the United States, followed by expansion into additional geographies and treatment settings.
What is lazertinib mesylate and how is it marketed?
Lazertinib is an oral, mutant-selective, irreversible EGFR inhibitor designed to inhibit sensitizing EGFR mutations and the T790M resistance mutation while reducing activity against wild-type EGFR. The active pharmaceutical ingredient is lazertinib mesylate.
| Item |
Details |
| U.S. brand |
Lazcluze |
| Active ingredient |
Lazertinib mesylate |
| Developer origin |
Yuhan and Genosco |
| Global commercial partner |
Johnson & Johnson |
| U.S. approval |
August 19, 2024 |
| FDA indication |
In combination with amivantamab for locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitutions |
| Dosage form |
Oral tablet |
| Combination product |
Rybrevant, amivantamab-vmjw |
| Key competitor |
Tagrisso, osimertinib |
| Regulatory pathway |
New drug application, not a biologic license application |
The FDA approved Lazcluze under the traditional approval pathway based primarily on the MARIPOSA phase 3 trial. The trial compared first-line lazertinib plus amivantamab with osimertinib monotherapy in EGFR-mutated advanced NSCLC. The combination produced median progression-free survival of 23.7 months versus 16.6 months for osimertinib, with a hazard ratio of approximately 0.70. [1]
What is the FDA regulatory status of Lazcluze?
Lazcluze received FDA approval on August 19, 2024. The approved regimen begins with a split-dose amivantamab schedule and continues with weekly or less frequent intravenous amivantamab administration alongside daily oral lazertinib, according to the product label. [2]
The regulatory positioning is commercially important because the label places lazertinib inside a combination regimen rather than as a direct monotherapy substitute for Tagrisso. Physicians must therefore evaluate the incremental efficacy of the combination against:
- Amivantamab infusion logistics.
- Infusion-related reactions.
- Venous thromboembolism risk.
- Patient willingness to receive prolonged intravenous treatment.
- Institutional capacity for administration and monitoring.
The FDA label includes boxed or prominent warnings and precautions related to infusion-related reactions, interstitial lung disease or pneumonitis, venous thromboembolic events, dermatologic toxicity, ocular toxicity and embryo-fetal toxicity. [2]
How does Lazcluze compare with Tagrisso?
Tagrisso remains the established first-line EGFR-mutated NSCLC standard in many treatment settings. Lazcluze competes through combination efficacy rather than tablet convenience.
| Commercial factor |
Lazcluze plus Rybrevant |
Tagrisso |
| Primary company |
Johnson & Johnson |
AstraZeneca |
| EGFR activity |
Mutant-selective irreversible inhibitor |
Irreversible mutant-selective EGFR inhibitor |
| Administration |
Oral lazertinib plus intravenous amivantamab |
Oral osimertinib |
| First-line PFS in MARIPOSA |
23.7 months |
16.6 months |
| Treatment burden |
Higher because of infusion administration |
Lower because of oral monotherapy |
| Key commercial argument |
Improved disease control and combination efficacy |
Established use, convenience and mature reimbursement |
| Main risk |
Infusion burden and combination toxicity |
Potential efficacy disadvantage in combination-comparison settings |
The MARIPOSA result gives Johnson & Johnson a credible basis to seek treatment share from Tagrisso. It does not guarantee rapid displacement. Osimertinib has a substantial physician familiarity advantage, broad clinical adoption and a simpler administration model. The competitive decision will likely vary by patient fitness, disease burden, central nervous system involvement, thrombosis risk, infusion access and local reimbursement.
The commercial question is whether the approximately seven-month median PFS advantage in MARIPOSA justifies the operational and safety burden of adding intravenous amivantamab. Johnson & Johnson’s answer is likely to rely on overall-survival maturation, real-world treatment persistence and payer acceptance.
What is the market size for lazertinib?
The addressable U.S. market is the first-line EGFR-mutated metastatic NSCLC population, not the entire lung-cancer market. EGFR mutations occur in approximately 10% to 15% of NSCLC cases in the United States, with higher frequencies in some Asian populations. Annual U.S. diagnosed incident cases with actionable EGFR mutations are commonly estimated in the tens of thousands, but the eligible first-line metastatic subset is materially smaller.
A practical market framework is:
| Market layer |
Commercial relevance |
| U.S. first-line EGFR exon 19/L858R metastatic NSCLC |
Initial high-value market |
| Europe and Japan |
Major expansion markets with established EGFR testing |
| China and other Asian markets |
Large mutation-positive population but pricing and local competition pressure |
| Earlier-stage EGFR-mutated disease |
Potential future expansion |
| Post-osimertinib resistance |
Separate opportunity, dependent on clinical data and regulatory approval |
| Combination with chemotherapy or other targeted agents |
Potential lifecycle expansion |
The current U.S. opportunity is a combination market. Even if Lazcluze achieves meaningful penetration, revenue will be influenced by how Johnson & Johnson allocates value between the oral component and Rybrevant. The combination also increases total treatment revenue per patient compared with an oral-only regimen, although payer scrutiny may intensify.
What is the financial trajectory for Lazcluze?
Lazcluze has limited standalone financial history because U.S. commercialization began in the second half of 2024. Johnson & Johnson reports oncology revenue at the segment and product level, but Lazcluze revenue may be presented separately only after it becomes material. Early sales therefore should be assessed through prescription uptake, Rybrevant demand, combination-treatment starts and geographic launches rather than through a mature product revenue series.
Base-case trajectory
The base case assumes:
- U.S. adoption increases gradually through community oncology and academic centers.
- Rybrevant administration capacity expands.
- Overall-survival data remain supportive.
- European and Asian launches proceed without major regulatory delay.
- Tagrisso retains a large share because of oral convenience.
Under this scenario, Lazcluze becomes a strategic growth product for Johnson & Johnson’s lung-cancer franchise, while Rybrevant captures a larger share of the combination economics.
Upside case
The upside case requires several factors to align:
- Sustained overall-survival benefit versus osimertinib.
- Improved dosing convenience for amivantamab.
- Strong central nervous system efficacy.
- Broad reimbursement for the combination.
- Rapid adoption in high-volume EGFR-mutated markets.
- Successful use in earlier-stage disease or additional resistance settings.
In this case, Lazcluze could become a major companion product for Rybrevant and support a multi-billion-dollar franchise. The combination’s revenue ceiling would be higher than Lazcluze monotherapy because each treated patient generates demand for both products.
Downside case
The downside case includes:
- Physician resistance to intravenous administration.
- Treatment discontinuation from infusion reactions or venous thromboembolism.
- Weak or inconclusive overall-survival differentiation.
- Payer restrictions requiring osimertinib use first.
- Delayed international reimbursement.
- Generic or patent-related erosion later in the 2030s.
In that scenario, Lazcluze may remain a specialist product used in selected fit patients rather than becoming the default first-line regimen.
What licensing deals support lazertinib commercialization?
Yuhan licensed lazertinib rights to Janssen Biotech, a Johnson & Johnson company, in 2018. The transaction gave Janssen rights outside South Korea and included upfront payments, development and regulatory milestones, and commercial royalties. Yuhan retained rights in South Korea under the announced arrangement. [3]
The deal structure gives Johnson & Johnson global control over commercialization while preserving economic participation for Yuhan. It also limits Johnson & Johnson’s discovery risk because the drug had already demonstrated clinical potential before the transaction.
Yuhan has continued to disclose milestone and royalty-related economic benefits associated with lazertinib. The precise economics are subject to contractual terms and company reporting. [3,4]
What patents protect Lazcluze and when could generic entry occur?
Lazcluze is a small-molecule drug and is eligible for patent protection and Orange Book listing through the U.S. NDA. Relevant protection may cover:
- Lazertinib compounds and salts.
- Pharmaceutical compositions.
- Tablet formulations.
- Dosing regimens.
- Combination treatment with amivantamab.
- Treatment of EGFR-mutated NSCLC.
- Manufacturing and crystalline-form technology.
A generic applicant could pursue an abbreviated new drug application and certify against listed patents, including through a Paragraph IV certification. That could trigger patent litigation and a potential 30-month stay of FDA approval under the Hatch-Waxman framework.
The principal commercial protection is likely to extend beyond the basic compound patent through formulation, method-of-use and combination patents. The effective generic-entry date will depend on the expiration and enforceability of the relevant patent family, any pediatric exclusivity, patent-term adjustment and litigation outcomes. The FDA approval itself does not create biosimilar protection because Lazcluze is a chemical drug, not a biologic.
No biosimilar pathway applies to lazertinib. Future competition will come through ANDA generics, not biosimilars.
What patent and manufacturing risks affect the market?
The most important IP risk is fragmentation across jurisdictions and patent categories. A compound patent may expire earlier than a method-of-use or combination patent. Generic companies may challenge selected patents while accepting others, creating litigation focused on whether the remaining claims cover the proposed label and commercial use.
Manufacturing IP can also delay practical competition if the drug requires protected polymorphs, salt forms, specialized intermediates or difficult-to-reproduce processes. Manufacturing barriers are less durable than enforceable composition-of-matter rights, but they can affect the cost and timing of generic entry.
Geographic protection is uneven. U.S., European, Japanese, Korean and Chinese patent families may have different filing dates, examination histories and expiration periods. A product can remain commercially protected in one market while facing generic competition in another.
What litigation and Paragraph IV risks exist?
Lazcluze entered the U.S. market recently, so the principal near-term legal risk is not current generic litigation but future ANDA challenges. The risk profile will rise as the product accumulates sales and approaches the end of its primary patent term.
Potential disputes include:
- Whether a generic label induces infringement of a patented EGFR-mutated NSCLC use.
- Whether combination claims cover use with amivantamab.
- Whether a salt or formulation claim is valid and infringed.
- Whether a patent was improperly listed in the Orange Book.
- Whether an ANDA applicant can launch at risk after a 30-month stay expires.
Because Lazcluze is commercially linked to Rybrevant, litigation involving amivantamab could also affect the combination’s market access even if lazertinib patents remain enforceable.
How strong is the commercial patent estate for lazertinib?
The estate is commercially stronger than a single compound patent because the product has multiple potential protection layers. Its practical strength depends on claim breadth, expiration timing and whether the claims cover the FDA-approved combination rather than only narrow use cases.
| Protection layer |
Strategic value |
| Composition of matter |
Highest value and broadest generic barrier |
| Salt or crystalline form |
Useful but more vulnerable to validity challenges |
| Formulation |
Can delay substitution if technically necessary |
| Method of treatment |
Important for label-based infringement |
| Combination with amivantamab |
Relevant to the marketed regimen |
| Manufacturing process |
Can raise entry costs but may not block all generics |
The strongest commercial scenario is a long-lived compound or composition patent reinforced by combination and method-of-use rights. The weaker scenario is an early-expiring basic patent with narrower secondary patents that generic applicants can design around.
What revenue exposure does Johnson & Johnson have?
Lazcluze creates both direct and indirect revenue exposure. Direct exposure comes from sales of the oral drug. Indirect exposure is larger because successful Lazcluze adoption increases Rybrevant utilization.
This structure reduces the risk that Lazcluze must become a blockbuster as a standalone medicine. Johnson & Johnson can benefit if the combination expands the total EGFR-mutated NSCLC treatment franchise, even when the oral product’s reported sales are modest.
The commercial exposure also creates concentration risk. If physicians reject the combination because of infusion logistics, both Lazcluze adoption and incremental Rybrevant demand could underperform. If the combination becomes a preferred regimen, the same linkage amplifies revenue growth.
What generic launch scenarios exist?
Early challenge scenario
A generic applicant files a Paragraph IV certification against one or more listed patents. Litigation begins, and the generic seeks approval after the statutory stay or a favorable court decision. This scenario creates market volatility well before actual launch.
Delayed entry scenario
Secondary patents covering the combination, formulation or method of treatment remain enforceable after the basic compound patent expires. Generic launch is delayed or limited to non-infringing labels.
At-risk launch scenario
A generic launches before final resolution after the stay expires. Johnson & Johnson may seek damages and an injunction. At-risk entry can cause rapid price erosion if multiple manufacturers launch.
Authorized or negotiated entry
Johnson & Johnson could settle litigation with a launch date before the latest patent expiration. The economics would depend on the settlement structure, authorized generic rights and restrictions imposed by antitrust law.
Key Takeaways
- Lazertinib mesylate is marketed in the United States as Lazcluze.
- FDA approval came on August 19, 2024, in combination with amivantamab for first-line EGFR exon 19 deletion or exon 21 L858R metastatic NSCLC.
- The MARIPOSA trial showed median progression-free survival of 23.7 months for Lazcluze plus Rybrevant versus 16.6 months for Tagrisso.
- The main commercial challenge is intravenous amivantamab administration, not lazertinib’s oral formulation.
- Johnson & Johnson’s revenue opportunity is a combined Lazcluze-Rybrevant franchise rather than Lazcluze sales alone.
- Tagrisso remains the principal competitive threat because of its established use and oral-only convenience.
- Lazcluze is a small molecule, so future competition will involve ANDA generics rather than biosimilars.
- Patent risk will center on compound, formulation, method-of-use, combination and manufacturing claims.
- Standalone Lazcluze revenue remains difficult to assess because the product has only a short U.S. commercial history and public reporting may combine or aggregate franchise results.
- Long-term value depends on overall-survival data, reimbursement, international launches, infusion logistics and the durability of the patent estate.
FAQs about lazertinib mesylate
Is lazertinib the same as osimertinib?
No. Both are third-generation irreversible EGFR inhibitors, but lazertinib is marketed as Lazcluze and osimertinib is marketed as Tagrisso. Their approved commercial regimens and clinical-development histories differ.
Is Lazcluze approved as monotherapy?
The U.S. approval is for Lazcluze in combination with amivantamab. It is not approved as a standalone first-line monotherapy under the cited FDA indication.
Does lazertinib treat EGFR exon 20 insertion mutations?
The U.S. Lazcluze indication covers EGFR exon 19 deletions and exon 21 L858R substitutions. Exon 20 insertion disease is a separate molecular and treatment category.
Who owns lazertinib?
Johnson & Johnson commercializes lazertinib outside territories retained by Yuhan under the 2018 licensing arrangement. Yuhan and its research affiliate Genosco originated the program.
What is the biggest commercial risk for Lazcluze?
The largest risk is adoption of the amivantamab combination. Physicians may value the MARIPOSA efficacy results but limit use because of infusion requirements, adverse events, treatment capacity and competition from oral osimertinib.
References
- Cho, B. C., Felip, E., Hayashi, H., et al. (2024). Amivantamab plus lazertinib in EGFR-mutated advanced non-small-cell lung cancer. New England Journal of Medicine.
- U.S. Food and Drug Administration. (2024). Lazcluze (lazertinib) prescribing information.
- Johnson & Johnson. (2018). Janssen enters into global collaboration and license agreement with Yuhan Corporation for lazertinib.
- Yuhan Corporation. (2024). Business reports and disclosures concerning lazertinib licensing milestones and royalties.
